Sanara MedTech announces publication of study on CellerateRX Surgical Powder

Sanara MedTech (SMTI) announced the publication of a peer-reviewed study evaluating the economic and clinical value of CellerateRX Surgical Powder in the Journal of Medical Economics. The study estimated the cost-effectiveness of adding CellerateRX as an adjunct to the standard of care for reducing postoperative complications in high-risk spinal surgery patients. The researchers found that the group treated with CellerateRX exhibited a dominant cost-effectiveness profile compared to the group treated with the standard of care alone. Specifically, the CellerateRX treatment arm generated $3,852 in cost savings and a 0.007 QALY gain per patient, yielding a net monetary benefit of $4,542. The primary contributors to cost savings were the avoidance of hospital readmissions and surgical revision procedures, which conservatively accounted for $2,238 and $835 of the total cost reductions, respectively.